DaVita
DVA
$189.32
+4.28%
DaVita Inc. is one of the largest providers of kidney dialysis services in the United States, operating over 3,200 outpatient dialysis facilities worldwide and treating approximately 300,000 patients annually, with roughly 35% US market share in a highly concentrated industry dominated by a duopoly alongside Fresenius. The company's business model is distinct in that government payers (primarily Medicare) account for about two-thirds of US dialysis revenue but commercial insurers—representing only about 10% of treated patients—generate nearly all of the company's US dialysis profits, making commercial reimbursement rates the single most important profit driver. The current investor narrative centers on a dramatic stock re-rating: shares surged from roughly $150 in early May 2026 to a 52-week high of $247.49 by late July before a sharp August reversal, with the market debating whether the mid-year rally reflected durable margin expansion and favorable Medicare rate updates or an overextended move vulnerable to reimbursement policy risk. More recently, the stock has stabilized in the $175–$184 range as investors weigh strong free cash flow generation and aggressive share buybacks against elevated leverage and the persistent overhang of government payer concentration.…
DVA
DaVita
$189.32
Related headlines
Investment Opinion: Should I buy DVA Today?
Rating: Buy. DaVita offers a compelling value proposition with a forward PE of 10.52x, a 20.3% upside to the consensus analyst target of $218.43, and a 5.19x price-to-free-cash-flow ratio, all supported by a 'buy' consensus rating from seven analysts. The core thesis is that the market is overly discounting reimbursement and leverage risks for a business with stable, non-discretionary demand, expanding margins, and aggressive capital returns that shrink the share count.
Supporting evidence is strong: revenue grew 5.96% year-over-year in Q1 2026 to $3.416 billion, gross margin expanded to 31.42% from 28.28% in the prior quarter, and net income rose 21.2% year-over-year to $197.53 million. Free cash flow of $1.493 billion on a trailing basis provides ample coverage for buybacks ($396.31 million in Q1 2026) and debt repayment ($346.09 million in Q1 2026). The EV/EBITDA of 9.11x is reasonable for a mature healthcare services provider, and the 0.72x price-to-sales ratio is well below the 2.70–4.21x range seen in 2022–2025, suggesting the stock is near the bottom of its historical valuation band.
The biggest risks that could invalidate the thesis are: (1) adverse Medicare rate updates that compress the government payer margin, (2) commercial insurer pushback on reimbursement rates that erodes the profit engine, and (3) a leverage-driven liquidity crunch if operating cash flow declines. This Buy rating would upgrade to a Strong Buy if the stock breaks above $200 with volume and forward PE remains below 12x, or downgrade to Hold if revenue growth decelerates below 3% or if commercial reimbursement rates decline by more than 5%. Relative to its own history and the broader healthcare sector, DaVita appears undervalued, trading at a 40–50% discount to sector PE multiples despite stable cash flows and a duopoly market position.
Sign up to view all
DVA 12-Month Price Forecast
DaVita presents a value opportunity with a forward PE of 10.52x, a 5.19x price-to-free-cash-flow ratio, and a 20.3% upside to the consensus analyst target, supported by stable cash flows and a duopoly market position. The company's 5.96% revenue growth and 21.2% net income growth in Q1 2026 demonstrate operating leverage, while aggressive buybacks reduce the share count and boost per-share earnings. However, the stock's 27.86% maximum drawdown and the wide analyst target range of $165 to $270 reflect genuine uncertainty about reimbursement policy and leverage. I would upgrade to high confidence if the stock breaks above $200 with strong volume and commercial reimbursement rates remain stable, or downgrade to bearish if Medicare rate updates turn unfavorable or if free cash flow declines below $1.2 billion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DaVita's 12-month outlook, with a consensus price target around $218.43 and implied upside of +15.4% versus the current price.
Average Target
$218.43
0 analysts
Implied Upside
+15.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $270
Analyst target range
Seven analysts cover DaVita with a consensus recommendation of "buy" (recommendation mean of 2.29 on a scale where lower is more bullish) and an average target price of $218.43, which implies +20.3% upside from the current price of $181.55. The consensus leans moderately bullish, supported by recent institutional actions: Deutsche Bank upgraded to Buy from Hold on May 6, 2026, while UBS has maintained a Buy rating through multiple updates (most recently July 10, 2026) and Barclays and Truist have stayed at Equal Weight and Hold respectively. The estimated EPS average of $18.12 (range $17.55–$18.95) and estimated revenue average of $15.89 billion provide the fundamental basis for the bullish targets, and the fact that no analyst carries a Sell rating suggests the bear case is not strongly represented in published research.
The target range is wide—$165.00 low to $270.00 high—representing a spread of $105, or roughly 64% of the current price, which signals meaningful disagreement about the company's trajectory. The high target of $270 assumes multiple expansion toward 15x forward earnings and successful defense of commercial reimbursement rates, potentially aided by favorable Medicare rate updates or international growth; the low target of $165 prices in margin compression, adverse reimbursement policy, or leverage-driven earnings pressure, and sits about 9% below the current price. The wide spread, combined with the stock's 27.86% max drawdown and the August collapse from $240 to $189, indicates high uncertainty and suggests investors should treat the consensus target as a directional signal rather than a precise forecast—the recent pattern of Hold/Equal Weight ratings from Barclays and Truist alongside Buy ratings from UBS and Deutsche Bank reflects a market genuinely split on whether the mid-year rally was justified or overdone.
Bulls vs Bears: DVA Investment Factors
The bull case rests on deep value (forward PE of 10.52x), robust free cash flow ($1.49 billion TTM), and aggressive buybacks that shrink the share count, while the bear case centers on government payer concentration, negative equity, and the stock's 27.86% drawdown from its July peak. Currently, the bull evidence appears slightly stronger: margins are expanding, net income grew 21.2% year-over-year, and the consensus analyst target of $218.43 implies 20.3% upside. However, the single most important tension is the sustainability of commercial reimbursement rates—if commercial insurers successfully pressure DaVita on rates, the profit engine that generates nearly all US dialysis earnings could erode rapidly, invalidating the value thesis. Conversely, if reimbursement holds and the August selloff proves to be an overreaction, the stock could re-rate toward the $218–$240 range.
Bullish
- Deep Value on Earnings: DVA trades at a trailing PE of 11.69x and forward PE of 10.52x, a 40–50% discount to the typical healthcare sector multiple in the high-teens to low-twenties. With estimated forward EPS of $18.12, the market is capitalizing earnings at a utility-like rate despite 5.96% revenue growth and expanding margins.
- Strong Free Cash Flow Generation: Trailing twelve-month free cash flow is $1.493 billion, and Q1 2026 operating cash flow of $320.83 million less capex of $102.02 million yielded $218.81 million of quarterly FCF. The price-to-free-cash-flow ratio of 5.19x is exceptionally low for a business with recurring, non-discretionary demand.
- Margin Expansion and Profit Growth: Q1 2026 gross margin improved to 31.42% from 28.28% in Q4 2025, and operating margin rose to 14.11% from 13.62% in Q1 2025. Net income of $197.53 million grew 21.2% year-over-year, demonstrating operating leverage despite modest revenue growth.
- Analyst Consensus Upside: Seven analysts have a consensus 'buy' rating (mean 2.29) with an average target price of $218.43, implying 20.3% upside from $181.55. The high target of $270 suggests potential for multiple expansion toward 15x forward earnings if reimbursement concerns ease.
Bearish
- Government Payer Concentration Risk: Government payers account for about two-thirds of US dialysis revenue, while commercial insurers—only 10% of patients—generate nearly all US dialysis profits. Any adverse Medicare rate update or policy change could disproportionately impact profitability, as the commercial margin buffer is thin relative to total revenue.
- Negative Equity and High Leverage: The debt-to-equity ratio of -23.12 and negative book value per share (PB of -15.02) reflect years of buyback-driven equity depletion. Interest expense of $145.13 million in Q1 2026 consumed a meaningful share of operating income, and the cash flow-to-debt ratio of 0.024 highlights limited financial flexibility.
- Severe Technical Damage: The stock collapsed from $240.09 on July 31 to $188.69 on August 5—a 21% single-week decline—and remains 26.6% below its 52-week high of $247.49. The 27.86% maximum drawdown and negative 3-month relative strength of -16.03 percentage points versus SPY indicate persistent stock-specific weakness.
- Wide Analyst Target Dispersion: The analyst target range spans $165 to $270, a $105 spread equal to 64% of the current price. This disagreement, with Barclays and Truist at Hold/Equal Weight while UBS and Deutsche Bank are at Buy, signals genuine uncertainty about whether the mid-year rally was justified or overdone.
DVA Technical Analysis
DaVita is in a recovery trend that has turned choppy, with the stock up 36.26% over the past year and an even stronger 58.55% year-to-date gain, yet the current price of $181.55 sits at just 55.7% of its 52-week range (52-week low of $101.00, high of $247.49). That mid-range positioning is unusual for a stock with such strong 1-year performance and signals that the bulk of the gains were captured in a sharp first-half surge that has since partially unwound—the stock is neither near highs (where momentum buyers chase) nor near lows (where value buyers step in), leaving it in a technically ambiguous zone. The 27.86% maximum drawdown confirms that the pullback from the July peak has been severe, and the fact that price is now 26.6% below the 52-week high means overhead resistance is heavy and well-defined.
Recent momentum has decelerated sharply and now diverges from the longer-term trend: the 1-month change is +2.75% and the 3-month change is -12.99%, while the 1-year change remains +36.26%. This divergence—positive short-term drift inside a negative 3-month trend—suggests the stock is attempting to base after the August collapse from $240.09 on July 31 to $188.69 on August 5, a single-week decline of roughly 21% that likely reflected an earnings or reimbursement-related shock. Relative strength tells the same story: DVA outperformed SPY by 20.04 percentage points over 1 year and by 46.47 points year-to-date, but underperformed by 16.03 points over the past 3 months, confirming that the recent weakness is stock-specific rather than market-driven. The stabilization around $176–$184 over the past five weeks, with the stock closing at $181.55 on September 11 versus a previous close of $181.33, suggests selling pressure has exhausted near-term, though volume of 767,845 shares is modest and offers limited confirmation of a durable bottom.
Key technical levels are clearly defined: support rests at the 52-week low of $101.00, with a more immediate support zone around $173–$176 where the stock found buyers in late August, while resistance sits at the 52-week high of $247.49, with intermediate resistance near $200 and the $240 area that capped the July rally. A breakout above $200 would signal that the August selloff was a temporary dislocation and could open a path back toward the highs, whereas a breakdown below $173 would threaten a retest of the $150 region and potentially the 52-week low. The stock's beta of 0.83 means it is roughly 17% less volatile than the broader market, which is notable for a healthcare services name with heavy leverage—this lower beta suggests the August drawdown was driven by company-specific news rather than systematic risk, and it implies position sizing can be somewhat larger than a high-beta equivalent for the same dollar risk, though the 27.86% max drawdown shows that idiosyncratic risk remains substantial.
Beta
0.83
0.83x market volatility
Max Drawdown
-27.9%
Largest decline past year
52-Week Range
$101-$247
Price range past year
Annual Return
+42.2%
Cumulative gain past year
| Period | DVA Return | S&P 500 |
|---|---|---|
| 1m | +5.1% | -2.0% |
| 3m | -9.4% | +1.4% |
| 6m | +27.2% | +15.0% |
| 1y | +42.2% | +15.7% |
| ytd | +65.3% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DVA Fundamental Analysis
DaVita's revenue trajectory is steady but modestly decelerating: Q1 2026 revenue of $3.416 billion grew 5.96% year-over-year against Q1 2025's $3.224 billion, continuing a pattern of low-to-mid single-digit growth across recent quarters (Q4 2025 revenue of $3.620 billion, Q3 2025 of $3.420 billion, Q2 2025 of $3.380 billion). The sequential trend shows revenue essentially flat from Q2 2025 through Q1 2026, hovering in the $3.38–$3.62 billion band, which reflects the mature, reimbursement-capped nature of the dialysis business rather than any demand problem. The US Dialysis and Related Lab Services segment accounts for $10.12 billion of annual revenue, underscoring that the company is essentially a single-segment US business with limited diversification, so growth must come from rate increases, mix shift toward commercial payers, or international expansion rather than new business lines. For investors, this means the investment case rests on margin and capital allocation rather than top-line acceleration.
Profitability is solid and margins have been expanding: Q1 2026 net income was $197.53 million on a 5.78% net margin, with gross margin of 31.42% and operating margin of 14.11%, while the trailing valuation data shows a 27.00% gross margin and 14.74% operating margin. Comparing recent quarters, gross margin improved from 28.28% in Q4 2025 to 31.42% in Q1 2026, and operating income rose to $481.89 million from $551.21 million in Q4 2025 (which benefited from seasonality), with operating margin holding in the 14–15% range versus 13.62% in Q1 2025—a clear year-over-year improvement. Net income of $197.53 million in Q1 2026 was up 21.2% from $162.92 million in Q1 2025, and EBITDA of $655.25 million carried a healthy 19.18% EBITDA margin. The one caveat is the reported ROE of -1.147 and negative book value per share (PB ratio of -15.02), which stems from years of buyback-driven equity depletion rather than operating losses—a critical distinction, since the company is genuinely profitable on an income statement basis.
Balance sheet and cash flow metrics reveal a leveraged but cash-generative business: free cash flow on a trailing twelve-month basis is $1.493 billion, Q1 2026 operating cash flow was $320.83 million against capital expenditure of $102.02 million (yielding $218.81 million of quarterly FCF), and the current ratio of 1.29 indicates adequate short-term liquidity. However, the debt-to-equity ratio of -23.12 and total debt-to-capitalization above 100% reflect negative shareholders' equity, and the cash flow-to-debt ratio of just 0.024 in Q1 2026 highlights that debt service consumes a meaningful share of cash generation—interest expense was $145.13 million in Q1 2026 alone. The company is aggressively returning capital, repurchasing $396.31 million of stock in Q1 2026 and $759.11 million in Q4 2025 while repaying $346.09 million of debt in Q1 2026, funded by internally generated cash rather than external financing. With a price-to-free-cash-flow ratio of roughly 5.19x on a PCF basis and FCF per share of $3.25, the cash generation is robust, but the combination of negative equity, heavy debt, and large buybacks means financial flexibility is thinner than headline FCF suggests.
Quarterly Revenue
$3.4B
2026-03
Revenue YoY Growth
+6.0%
YoY Comparison
Gross Margin
31.4%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DVA Overvalued?
Because DaVita is profitable—Q1 2026 net income of $197.53 million and trailing EPS of $0.076 (distorted by the data source's per-share convention) with estimated forward EPS of $18.12—the PE ratio is the appropriate primary metric. The trailing PE of 11.69x versus a forward PE of 10.52x implies the market expects only modest earnings growth of roughly 11% over the next year, a narrow gap that signals limited optimism about acceleration. On a price-to-sales basis, the stock trades at just 0.72x sales and 1.87x EV/sales, while EV/EBITDA of 9.11x is the most informative multiple for this capital-intensive, leveraged business and sits in reasonable territory for a mature healthcare services provider.
Relative to the broader healthcare sector, DaVita screens as a value name: a trailing PE of 11.69x and forward PE of 10.52x are well below the typical healthcare sector average in the high-teens to low-twenties, representing a discount of roughly 40–50%, and the 0.72x PS ratio is similarly depressed versus sector norms. This discount is partly justified by the company's structural issues—negative book value (PB of -15.02), debt-to-equity of -23.12, and heavy government payer concentration—but the 9.11x EV/EBITDA and 5.19x price-to-cash-flow suggest the market is pricing in substantial reimbursement and leverage risk that may be overstated given $1.49 billion in trailing FCF. The forward PE of 10.52x against estimated EPS of $18.12 implies the market is capitalizing earnings at a rate more typical of a no-growth utility than a business with 5.96% revenue growth and expanding margins.
Historically, DaVita's PE has ranged from a low of 8.75x (Q3 2023) to a high of 24.56x (Q4 2022), with the current 11.69x sitting in the lower third of that band and below the 13.11x recorded in Q1 2026 and the 15.89x in Q3 2025. The PS ratio of 0.72x is dramatically below the 2.70–4.21x range seen throughout 2022–2025, though this comparison is distorted by the data source's inconsistent share-count treatment; the historical ratios table shows PS ratios of 2.70x–4.21x across 2022–2025, making the current 0.72x appear anomalously low. Taken together, the valuation sits near the bottom of its own historical band on both PE and PS, which could signal a genuine value opportunity given stable cash flows—or reflect the market's growing concern about reimbursement policy, leverage, and the sustainability of commercial payer profits.
PE
11.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~19x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.1x
Enterprise Value Multiple
Investment Risk Disclosure
DaVita's financial risks are dominated by its leveraged balance sheet and negative equity. The debt-to-equity ratio of -23.12 and negative book value per share (PB of -15.02) stem from years of buyback-driven equity depletion, leaving the company with thin financial flexibility. Interest expense of $145.13 million in Q1 2026 consumed roughly 30% of operating income of $481.89 million, and the cash flow-to-debt ratio of just 0.024 indicates that debt service absorbs a significant portion of cash generation. While trailing free cash flow of $1.493 billion is robust, the combination of $396.31 million in Q1 2026 buybacks, $346.09 million in debt repayment, and $102.02 million in capex means the company is returning capital at a pace that could strain liquidity if operating cash flow dips. Additionally, revenue concentration in a single segment—US Dialysis and Related Lab Services at $10.12 billion annually—exposes the company to any structural change in dialysis demand or reimbursement.
Market and competitive risks are significant given DaVita's premium-free valuation but heavy regulatory exposure. The stock's beta of 0.83 suggests it is 17% less volatile than the broader market, yet the 27.86% maximum drawdown and the 21% single-week August collapse show that idiosyncratic, policy-driven shocks can be severe. The duopoly structure with Fresenius provides pricing stability, but it also invites regulatory scrutiny on reimbursement rates, and any adverse Medicare rate update could compress margins. The wide analyst target range of $165 to $270 (a 64% spread) reflects deep disagreement about the sustainability of commercial reimbursement, and the recent pattern of Hold/Equal Weight ratings from Barclays and Truist alongside Buy ratings from UBS and Deutsche Bank suggests the market is genuinely split. Sector rotation risk is also present: healthcare services stocks with government payer exposure can underperform if policy uncertainty rises, and the stock's 3-month relative underperformance of -16.03 percentage points versus SPY confirms it is currently out of favor.
The worst-case scenario for DaVita would be a combination of adverse Medicare rate updates and commercial insurer pushback on reimbursement rates, which would compress the profit engine that generates nearly all US dialysis earnings. In this scenario, the stock could retest its 52-week low of $101.00, representing a decline of approximately 44% from the current price of $181.55. The analyst low target of $165 implies a more moderate downside of about 9%, but the 52-week low and the 27.86% max drawdown suggest that a severe policy shock could drive a much deeper selloff. If commercial reimbursement rates were cut by 10% and Medicare rates remained flat, the impact on net income could be disproportionate given that commercial payers generate nearly all profits; a 20% decline in commercial profit contribution could reduce EPS by 15–20%, potentially pushing the stock toward the $140–$150 range. Investors should be prepared for drawdowns of 30–45% in a bear scenario, with the $101 low serving as the ultimate downside reference.
FAQ
The most severe risk is government payer concentration: two-thirds of US dialysis revenue comes from government payers, and any adverse Medicare rate update could disproportionately impact profitability since commercial insurers generate nearly all US dialysis profits. Second, the leveraged balance sheet with negative equity (debt-to-equity of -23.12) and interest expense of $145.13 million in Q1 2026 limits financial flexibility and exposes the company to rising interest rates. Third, competitive and regulatory risks include potential changes to dialysis reimbursement policy or pressure from insurers, which could compress margins. Fourth, the stock's 27.86% maximum drawdown and 21% single-week August decline demonstrate that idiosyncratic, policy-driven shocks can cause severe price damage. Ranked by severity: reimbursement policy risk is highest, followed by leverage/liquidity risk, then competitive pressure, and finally valuation compression risk.
The 12-month forecast includes three scenarios: a bull case with 25% probability targeting $240–$270, a base case with 55% probability targeting $200–$230, and a bear case with 20% probability targeting $101–$165. The base case is most likely, assuming stable reimbursement, mid-single-digit revenue growth, and modest margin expansion, leading to a gradual re-rating toward the analyst average target of $218.43. The bull case requires favorable Medicare rate updates and successful defense of commercial reimbursement rates, while the bear case assumes adverse policy changes or a leverage-driven liquidity event. The key assumption behind the base case is that free cash flow remains above $1.4 billion, funding buybacks and debt reduction without straining liquidity.
DVA appears undervalued on both absolute and relative bases. The forward PE of 10.52x and trailing PE of 11.69x are 40–50% below the typical healthcare sector multiple in the high-teens to low-twenties, and the 0.72x price-to-sales ratio is well below the 2.70–4.21x range seen in 2022–2025. The EV/EBITDA of 9.11x is reasonable for a mature, capital-intensive healthcare services provider, and the 5.19x price-to-free-cash-flow ratio is exceptionally low. The market appears to be pricing in substantial reimbursement and leverage risk, capitalizing earnings at a rate more typical of a no-growth utility despite 5.96% revenue growth and expanding margins. If the company can maintain commercial reimbursement rates and continue margin expansion, the stock could re-rate toward 13–15x forward earnings, implying a fair value of $235–$270.
From a risk/reward perspective, DVA offers a favorable setup with 20.3% upside to the consensus analyst target of $218.43 and a forward PE of just 10.52x, well below the healthcare sector average. The company generates $1.49 billion in trailing free cash flow and grew net income 21.2% year-over-year in Q1 2026, yet the stock trades at only 5.19x free cash flow, suggesting deep value. However, the biggest downside risk is reimbursement policy: government payers account for two-thirds of revenue, and any adverse Medicare rate update could compress margins and drive the stock toward its 52-week low of $101. For value-oriented investors with a tolerance for policy risk and a 12–18 month horizon, DVA is a good buy at current levels, but position sizing should account for the potential 30–45% drawdown in a bear scenario.
DVA is best suited for a medium-to-long-term investment horizon of at least 12–18 months, given its value characteristics, stable cash flows, and the time needed for reimbursement policy clarity to emerge. The stock's beta of 0.83 indicates lower volatility than the broader market, but the 27.86% maximum drawdown and policy-driven shocks make it unsuitable for short-term trading unless one has a specific catalyst-driven thesis. The company pays no dividend (payout ratio of 0), so returns depend entirely on capital appreciation and buyback-driven EPS growth. Earnings visibility is moderate, with quarterly revenue in a stable $3.38–$3.62 billion band, but policy risk introduces uncertainty. A minimum holding period of 12 months is recommended to allow for potential multiple expansion and to ride out reimbursement-related volatility.